Evidence map›Paper›PMID 42651097›Full record

ReviewBrain sciences2026

The Role of the NMDA Receptor in the Treatment of Psychiatric and Neurological Diseases.

Stan Heath, Madeline Ruzicka, Taylor McLoon, Daya Gupta, Onyinyechi Emeri, Zikora Nnabugwu, Adegoke Adeniji, Christopher Brackett, Steven Slack, Ayodeji Agbowuro

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stan HeathSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Madeline RuzickaSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Taylor McLoonSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Daya GuptaSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Onyinyechi EmeriSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Zikora NnabugwuSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Adegoke AdenijiSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Christopher BrackettSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Steven SlackSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.
Ayodeji AgbowuroSouth University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA.ORCID 0009-0006-4257-7002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor widely expressed in the CNS and in peripheral tissues where it mediates crucial physiological functions and its dysregulation has been linked to a host of neurological and psychiatric disorders including Alzheimer's disease, schizophrenia, epilepsy, and chronic pain. This work highlights the therapeutic potential in targeting the NMDAR in these disease states by providing a holistic analysis of the existing literature focused on the molecular role of the receptor in applicable disease conditions. While several drugs targeting the NMDAR have been approved for clinical use, many more are in clinical and preclinical development. A significant part of this review assesses the chemical and pharmacological attributes of these molecules and provides a prognostic perspective for their use.

Indexed as

neurological disordersNMDARpsychiatric disorderstherapeutic potential

Identifiers

PMID42651097
PMCPMC13510856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.